Tax
Income Tax at U.S. Statutory Rate
Vertex Pharmaceuticals Income Tax at U.S. Statutory Rate remained flat by 0.0% to $243.78M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 464333333233.3%, from $0.05 to $243.78M. Over 2 years (FY 2023 to FY 2025), Income Tax at U.S. Statutory Rate shows an upward trend with a 6814100.9% CAGR.
Analysis
StatementIncome Statement
SectionTax
CategoryRisk
SignalContext dependent
VolatilityStable
First reportedQ1 2023
Last reportedQ4 2025Feb 13, 2026
How to read this metric
Used as a benchmark to evaluate how much the company's actual tax rate deviates from the statutory norm.
Detailed definition
The theoretical income tax expense calculated by applying the U.S. federal statutory tax rate to the company's income be...
Peer comparison
Standard disclosure in the tax rate reconciliation table for all U.S. public companies.
Metric ID:
cat_income_tax_at_statutory_rateHistorical Data
3 years
| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $0.21 | $0.21 | $975.10M |
| YoY Change | — | +0.0% | >999% |
Range$0.21 – $975.10M
CAGR>999%
Avg YoY Growth>999%
Median YoY Growth>999%
Current Streak2+ years growth
Income Tax at U.S. Statutory Rate at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's income tax at u.s. statutory rate?
- Vertex Pharmaceuticals (VRTX) reported income tax at u.s. statutory rate of $243.78M in Q4 2025.
- How has Vertex Pharmaceuticals's income tax at u.s. statutory rate changed year-over-year?
- Vertex Pharmaceuticals's income tax at u.s. statutory rate increased by 464333333233.3% year-over-year, from $0.05 to $243.78M.
- What is the long-term trend for Vertex Pharmaceuticals's income tax at u.s. statutory rate?
- Over 2 years (2023 to 2025), Vertex Pharmaceuticals's income tax at u.s. statutory rate has grown at a 6814100.9% compound annual growth rate (CAGR), from $0.21 to $975.10M.
- What does income tax at u.s. statutory rate mean?
- The tax expense calculated using the standard federal tax rate.